MeiraGTx Holdings Investor Relations Material
Latest events
Study Update
MeiraGTx Holdings
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies
Latest reports from MeiraGTx Holdings plc
Access all reports
MeiraGTx Holdings plc is a clinical-stage gene therapy company dedicated to developing potentially curative treatments for patients suffering from serious diseases. The company's research and development efforts are currently concentrated on six clinical programs, which include treatments for four types of ocular diseases, a salivary gland condition, and Parkinson’s disease. MeiraGTx's approach is particularly focused on areas with significant unmet medical needs, such as diseases of the eye, salivary gland, and central nervous system. The company is headquartered in New York and London, and its shares are listed on the Nasdaq.
Key slides for MeiraGTx Holdings plc
Corporate Presentation
MeiraGTx Holdings plc
Corporate Presentation
MeiraGTx Holdings plc
Latest articles
Qualcomm: Quality Communication and Semiconductor Innovation
Founded in 1985, Qualcomm has transformed the digital communication industry with CDMA technology and its advanced semiconductor business.
13 Sep 2024
Strong Opinions, Loosely Held: Pontus Dackmo on Flexibility and Market Psychology
After a two-decade career in finance, Pontus Dackmo co-founded Protean Funds Scandinavia in 2022, where he now serves as CEO and Investment Manager.
4 Sep 2024
Novo Nordisk: The Danish Pharmaceutical Titan Revolutionizing Global Healthcare
Novo Nordisk's rise to becoming Europe's largest company, reshaping global healthcare and Denmark's economy.
5 Sep 2024
Ticker symbol
MGTX
Country
🇺🇸 United States